Replies to post #492293 on Anavex Life Sciences Corp (AVXL)

[rx7171]

My concern is we won’t get any 3-71 data until there is a substantial time after the trial conclusion to look for a delayed negative signal and durability of response.

This has not been mentioned by the company but we have been blindsided by unexpected delays in the past, such as two years waiting for the peer reviewed article on the AD 2b/3 trial.
That actually may have been intentional to give time for the OLE data to come available to supplement the MAA submittal.

[tredenwater2]

Falconner well stated! Question for you with respect to the consortium Anavex spent the better part of 2 yrs in. In your opinion did the consortium create/agree on parameters for showing efficacy in trials for the treatment of Schizophrenia to the point where Anavex may be able to use them in this phase 2, 2 part trial?

[Steady_T]

It may be bioactive in micrograms, but the trials docs say it is administered in 30 and 60 milligram doses.

One might presume that is the amount of active ingredient in the dose.

As I recall the P1 trial found that it was well tolerated up to 200 milligram amounts with an apparent ceiling at 160 mg..

[jfk]

Falconer,66a what gives you confidence that the AVXL test protocols for various indications are sound and will pass muster when the results are received? Majority of ALZ company trial results are negated due to poor design (thinking about INMB today, and AVXL's Rett)...What are you able to capably discern that the highly paid employees of these biotechs manage to get wrong, and manage to capably kill most of these companies and their dreams?